<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01866163</url>
  </required_header>
  <id_info>
    <org_study_id>LP0053-1001</org_study_id>
    <nct_id>NCT01866163</nct_id>
  </id_info>
  <brief_title>LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris</brief_title>
  <official_title>LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to compare the efficacy of treatment with LEO 90100 to that of
      treatment with vehicle for up to 4 weeks in subjects with psoriasis vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Success According to IGA</measure>
    <time_frame>4 weeks</time_frame>
    <description>Subjects with 'treatment success' ('clear' or 'almost clear' for subjects with at least moderate disease at baseline, 'clear' for subjects with mild disease at baseline) according to the Investigators' global assessment of disease severity (IGA) at Week 4.
The 5 point IGA scale: 1 = clear, 2 = almost clear, 3 = mild, 4 = moderate and 5 = severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>m-PASI at Week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>The investigator assessed the extent and severity of the three clinical signs (redness, thickness, and scaliness) on the arms, trunk and legs. These assessments were converted to an Modified Psoriasis Area and Severity Index (m-PASI).
m-PASI (excluding head) assessed at week 4 (adjusted for the effect of (pooled) centre and baseline m-PASI.
The m-PASI score range from 0 (best) to 64.8 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>m-PASI at Week 1</measure>
    <time_frame>1 week</time_frame>
    <description>The investigator assessed the extent and severity of the three clinical signs (redness, thickness, and scaliness) on the arms, trunk and legs. These assessments were converted to an Modified Psoriasis Area and Severity Index (m-PASI).
m-PASI (excluding head) assessed at week 4 (adjusted for the effect of (pooled) centre and baseline m-PASI.
The m-PASI score range from 0 (best) to 64.8 (worst).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">426</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>LEO 90100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aerosol foam vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 90100</intervention_name>
    <arm_group_label>LEO 90100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical diagnosis of psoriasis vulgaris of at least 6 months duration involving the
             trunk and/or limbs

          -  Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and
             skin folds) involving 2-30% of the Body Surface Area (BSA)

          -  An Investigator's Global Assessment of disease severity (IGA) of at least mild at Day
             0 (Visit 1)

          -  A modified PASI (m-PASI) score of at least 2 at Day 0 (Visit 1)

          -  A target lesion of a minimum of 5 cm at its longest axis and preferably not located on
             the extensor surface on an elbow or knee, scoring at least 1 for each of redness,
             thickness and scaliness, and at least 4 in total by the Investigator's Assessment of
             Severity of the Target Lesion

        Exclusion Criteria:

          -  Systemic treatment with biological therapies, whether marketed or not, with a possible
             effect on psoriasis vulgaris within the following time periods prior to randomisation:

               -  etanercept - within 4 weeks prior to randomisation

               -  adalimumab, infliximab - within 8 weeks prior to randomisation

               -  ustekinumab - within 16 weeks prior to randomisation

               -  other products - within 4 weeks/5 half-lives prior to randomisation (whichever is
                  longer)

          -  Systemic treatment with all other therapies with a possible effect on psoriasis
             vulgaris (e.g., corticosteroids, retinoids, methotrexate, ciclosporin and other
             immunosuppressants) within 4 weeks prior to randomisation.

          -  Subjects who have received treatment with any nonmarketed drug substance (i.e. a drug
             which has not yet been made available for clinical use following registration) within
             4 weeks/5 half-lives (whichever is longer) prior to randomisation.

          -  PUVA therapy within 4 weeks prior to randomisation.

          -  UVB therapy within 2 weeks prior to randomisation.

          -  Topical anti-psoriatic treatment on the trunk and limbs (except for emollients) within
             2 weeks prior to randomisation.

          -  Topical treatment on the face, scalp and skin folds with corticosteroids, vitamin D
             analogues or prescription shampoos within 2 weeks prior to randomisation.

          -  Planned initiation of, or changes to, concomitant medication that could affect
             psoriasis vulgaris (e.g. beta blockers, antimalarial drugs, lithium, ACE inhibitors)
             during the trial.

          -  Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.

          -  Previously randomised in this trial or any previously conducted trial of LEO 90100.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Leonardi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Dermatology</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2013</study_first_submitted>
  <study_first_submitted_qc>May 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2013</study_first_posted>
  <results_first_submitted>November 13, 2015</results_first_submitted>
  <results_first_submitted_qc>April 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2016</results_first_posted>
  <disposition_first_submitted>July 13, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 13, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 3, 2015</disposition_first_posted>
  <last_update_submitted>April 6, 2016</last_update_submitted>
  <last_update_submitted_qc>April 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Subject First Visit: 17-Jun-2013 Last Subject Last Visit: 02-Oct-2013</recruitment_details>
      <pre_assignment_details>Prior to randomisation, the subject entered a washout phase (if required) where anti-psoriatic treatment and other relevant medication/treatments were discontinued as defined by the exclusion criteria. The wash-out/screening phase could last for up to 4 weeks, depending on which disallowed treatments the subject received.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LEO 90100</title>
          <description>LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>Aerosol foam vehicle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="323"/>
                <participants group_id="P2" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="313"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LEO 90100</title>
          <description>LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>Aerosol foam vehicle</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="323"/>
            <count group_id="B2" value="103"/>
            <count group_id="B3" value="426"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.2" spread="13.9"/>
                    <measurement group_id="B2" value="46.0" spread="13.2"/>
                    <measurement group_id="B3" value="50.0" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Success According to IGA</title>
        <description>Subjects with ‘treatment success’ (‘clear’ or ‘almost clear’ for subjects with at least moderate disease at baseline, ‘clear’ for subjects with mild disease at baseline) according to the Investigators’ global assessment of disease severity (IGA) at Week 4.
The 5 point IGA scale: 1 = clear, 2 = almost clear, 3 = mild, 4 = moderate and 5 = severe</description>
        <time_frame>4 weeks</time_frame>
        <population>All randomised subjects were included in the full analysis set and analysed for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 90100</title>
            <description>LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Aerosol foam vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Success According to IGA</title>
          <description>Subjects with ‘treatment success’ (‘clear’ or ‘almost clear’ for subjects with at least moderate disease at baseline, ‘clear’ for subjects with mild disease at baseline) according to the Investigators’ global assessment of disease severity (IGA) at Week 4.
The 5 point IGA scale: 1 = clear, 2 = almost clear, 3 = mild, 4 = moderate and 5 = severe</description>
          <population>All randomised subjects were included in the full analysis set and analysed for efficacy.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Multiple imputations were used to handle missing data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mantel Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>30.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.72</ci_lower_limit>
            <ci_upper_limit>94.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>m-PASI at Week 4</title>
        <description>The investigator assessed the extent and severity of the three clinical signs (redness, thickness, and scaliness) on the arms, trunk and legs. These assessments were converted to an Modified Psoriasis Area and Severity Index (m-PASI).
m-PASI (excluding head) assessed at week 4 (adjusted for the effect of (pooled) centre and baseline m-PASI.
The m-PASI score range from 0 (best) to 64.8 (worst).</description>
        <time_frame>4 weeks</time_frame>
        <population>All randomised subjects were included in the full analysis set and analysed for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 90100</title>
            <description>LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Aerosol foam vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>m-PASI at Week 4</title>
          <description>The investigator assessed the extent and severity of the three clinical signs (redness, thickness, and scaliness) on the arms, trunk and legs. These assessments were converted to an Modified Psoriasis Area and Severity Index (m-PASI).
m-PASI (excluding head) assessed at week 4 (adjusted for the effect of (pooled) centre and baseline m-PASI.
The m-PASI score range from 0 (best) to 64.8 (worst).</description>
          <population>All randomised subjects were included in the full analysis set and analysed for efficacy.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" lower_limit="1.74" upper_limit="2.35"/>
                    <measurement group_id="O2" value="5.33" lower_limit="4.79" upper_limit="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The mean value and CIs were adjusted for the effect of pooled centres and baseline m-PASI. Multiple imputation was used to handle missing data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.90</ci_lower_limit>
            <ci_upper_limit>-2.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>m-PASI at Week 1</title>
        <description>The investigator assessed the extent and severity of the three clinical signs (redness, thickness, and scaliness) on the arms, trunk and legs. These assessments were converted to an Modified Psoriasis Area and Severity Index (m-PASI).
m-PASI (excluding head) assessed at week 4 (adjusted for the effect of (pooled) centre and baseline m-PASI.
The m-PASI score range from 0 (best) to 64.8 (worst).</description>
        <time_frame>1 week</time_frame>
        <population>All randomised subjects were included in the full analysis set and analysed for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 90100</title>
            <description>LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Aerosol foam vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>m-PASI at Week 1</title>
          <description>The investigator assessed the extent and severity of the three clinical signs (redness, thickness, and scaliness) on the arms, trunk and legs. These assessments were converted to an Modified Psoriasis Area and Severity Index (m-PASI).
m-PASI (excluding head) assessed at week 4 (adjusted for the effect of (pooled) centre and baseline m-PASI.
The m-PASI score range from 0 (best) to 64.8 (worst).</description>
          <population>All randomised subjects were included in the full analysis set and analysed for efficacy.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.66" lower_limit="4.41" upper_limit="4.90"/>
                    <measurement group_id="O2" value="5.93" lower_limit="5.50" upper_limit="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The mean value and CIs were adjusted for the effect of pooled centres and baseline m-PASI. Multiple imputation was used to handle missing data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.76</ci_lower_limit>
            <ci_upper_limit>-0.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LEO 90100</title>
          <description>LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>Aerosol foam vehicle</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Substance induced psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.6</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pain</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Application site erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Application site oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>LEO acknowledges the investigators’ right to publish the results of the trial, irrespective of outcome. Pubs/presentations by investigator(s) shall not be made before the results of a joint publication is public. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <phone>+45 44945888</phone>
      <email>ctr.disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

